GSK Says RSV Vaccine Candidate Showed Significant Efficacy in Phase 3 Trial
June 10 2022 - 1:44AM
Dow Jones News
By Anthony O. Goriainoff
GSK PLC said Friday that its respiratory syncytial virus, or
RSV, vaccine candidate showed a statistically significant and
clinically meaningful efficacy in adults aged 60 and over.
The London-listed pharmaceutical company said an efficacy
analysis of the AReSVi 006 Phase 3 trial showed it offered
exceptional protection for older adults from the serious
consequences of RSV infection.
The company said it would start to engage with regulators
immediately and that it expected regulatory submissions in the
second half of the year.
"The AReSVi 006 trial will continue to evaluate both an annual
revaccination schedule and longer-term protection over multiple
seasons following one dose of the RSV older adult vaccine
candidate," the company said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 10, 2022 02:29 ET (06:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024